SAN CARLOS, Calif., Jan 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference in New York at the Grand Hyatt New York Hotel on Tuesday, February 5, 2008 at 1:00 p.m. ET.
The presentation and Q&A session will be accessible via a live audio-only Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 19, 2008.
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
Nektar Therapeutics
650-631-3100 Phone
650-631-3150 Fax
http://www.nektar.com
SOURCE Nektar Therapeutics
http://www.nektar.com/
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX